/ WHAT YOU WILL RECEIVE
Real photographs of your peptides — boxed, lot-labeled, and shipped in plain unmarked packaging from our partner research lab.
More batch photos and lab footage coming soon.
PEPTIDE SEQUENCE · STRUCTURE NOTE
Y-Aib-EGTFTSDYSI-Aib-LDKIAQK-Aib-AFIEYLLEGGPSSGAPPPS-NH2
Dual GIP / GLP-1 receptor agonist with C20 diacid fatty-acid modification for extended half-life.
⏱ HALF-LIFE · PHARMACOKINETIC PROFILE
Dual GIP / GLP-1 receptor agonist
~5 days
C20 fatty-diacid modification extends plasma half-life for once-weekly dosing.
GLP-1s · RESEARCH GRADE
Tirzepatide
30mg · Lyophilized Vial
Sold Out
This variant is temporarily unavailable — drop your email below to get notified.
Dual GIP/GLP-1 receptor agonist — next-generation metabolic research compound.
UNIT PRICE
$110 USD
$130
Reconstitution required
This compound requires bacteriostatic water for reconstitution. Don't forget to add a 10mL vial of BAC water to your order — available in Lab Supplies.
HOW LONG WILL IT LAST YOU?
Enter your research protocol and vial quantity — see exactly how many weeks your order covers.
Each 30mg vial lasts
6 weeks
Your 30mg vial lasts
6weeks
≈ 42 days · 6.0 doses per vial
FOR RESEARCH USE ONLY
Not for human consumption. Intended for laboratory and in-vitro research applications./ RESEARCH INFORMATION · STANDARDIZED PROFILE
Full breakdown.
Every compound on Helixora ships with a consistent six-section research profile so you can compare and reference quickly.
Overview & Classification
Dual GIP/GLP-1 receptor agonist — first-in-class incretin co-agonist for metabolic research.
Type
Dual-agonist peptide (39 residues)
Derivation
Synthetic — recombinant or solid-phase synthesis with C20 fatty-diacid conjugation.
Structural
Modified GIP backbone with GLP-1 receptor activity; albumin-binding side chain extends half-life to ~5 days.
Mechanism of Action
- ·GLP-1R agonism: glucose-dependent insulin release + gastric-emptying delay
- ·GIP receptor agonism: insulinotropic + adipocyte-signaling effects
- ·Combined activity reduces postprandial glucose excursions and food intake in research models
- ·Activates intracellular cAMP-PKA signaling in pancreatic β-cells
Research Highlights
- ·Significant body-weight reductions in research-cohort studies vs single-agonist comparators
- ·Improved HbA1c in T2D research models
- ·Cardiometabolic markers showed favorable shifts in long-duration trials
Research Usage Parameters
- ·Research dose range: 2.5–15mg subcutaneous once weekly
- ·Standard titration: 2.5mg weeks 1–4, escalate by 2.5mg every 4 weeks
- ·Common protocol duration: 24–72 weeks
Pharmacological Profile
Half-life
~5 days
Absorption
Subcutaneous; near-complete bioavailability
Distribution
Albumin-bound; restricted CNS distribution
Safety Profile
- ·Most common: nausea, diarrhea, decreased appetite — dose-dependent, typically improves with continued dosing
- ·Pancreatitis signal monitored in research protocols
- ·Contraindicated for research with MTC or MEN2 history
- ·Caution with concomitant secretagogues — hypoglycemia risk
/ RESEARCH DOSSIER